Decrypting the potency of anti-cancer therapeutics by using mass spectrometry to quantify post-translational modifications

Sophie A Herbst; Forest M White

doi:10.1016/j.crmeth.2023.100483

Decrypting the potency of anti-cancer therapeutics by using mass spectrometry to quantify post-translational modifications

Cell Rep Methods. 2023 May 22;3(5):100483. doi: 10.1016/j.crmeth.2023.100483.

Authors

Sophie A Herbst^{1

2}, Forest M White^{1

2}

Affiliations

¹ Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139 USA.
² Center for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Abstract

In a recent issue of Science, Zecha et al.¹ present decryptM, an approach aimed at defining the mechanisms of action of anti-cancer therapeutics through systems-level analysis of protein post-translational modifications (PTMs). By using a broad range of concentrations, decryptM generates drug response curves for each detected PTM, enabling identification of drug effects at different therapeutic doses.

Publication types

News
Research Support, N.I.H., Extramural

MeSH terms

Humans
Mass Spectrometry / methods
Neoplasms* / drug therapy
Protein Processing, Post-Translational*
Proteins

Substances

Proteins

Abstract

Publication types

MeSH terms

Substances

Grants and funding